GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (XTAE:ENLV) » Definitions » Cyclically Adjusted FCF per Share

Enlivex Therapeutics (XTAE:ENLV) Cyclically Adjusted FCF per Share : ₪-46.65 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Enlivex Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Enlivex Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2024 was ₪-0.642. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₪-46.65 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-05-30), Enlivex Therapeutics's current stock price is ₪3.367. Enlivex Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was ₪-46.65. Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Enlivex Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Enlivex Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics Cyclically Adjusted FCF per Share Chart

Enlivex Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -50.07 -52.24 -46.65

Enlivex Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.24 -50.65 -53.30 -49.29 -46.65

Competitive Comparison of Enlivex Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Enlivex Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enlivex Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.642/133.1571*133.1571
=-0.642

Current CPI (Dec. 2024) = 133.1571.

Enlivex Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -35.152 99.621 -46.985
201506 -28.430 100.684 -37.599
201509 -31.244 100.392 -41.441
201512 -36.028 99.792 -48.074
201603 -38.285 100.470 -50.741
201606 -48.756 101.688 -63.844
201609 -24.454 101.861 -31.967
201612 -25.278 101.863 -33.044
201703 -23.678 102.862 -30.652
201706 -16.511 103.349 -21.273
201709 -8.952 104.136 -11.447
201712 25.648 104.011 32.835
201803 -8.021 105.290 -10.144
201806 -4.572 106.317 -5.726
201809 -5.672 106.507 -7.091
201812 -11.090 105.998 -13.932
201903 -8.319 107.251 -10.328
201906 -6.455 108.070 -7.953
201909 -0.711 108.329 -0.874
201912 -0.573 108.420 -0.704
202003 0.227 108.902 0.278
202006 -0.991 108.767 -1.213
202009 -0.709 109.815 -0.860
202012 -1.522 109.897 -1.844
202103 -0.534 111.754 -0.636
202106 -0.901 114.631 -1.047
202109 -0.827 115.734 -0.951
202112 -1.458 117.630 -1.650
202203 -0.805 121.301 -0.884
202206 -2.416 125.017 -2.573
202209 -1.482 125.227 -1.576
202212 -1.406 125.222 -1.495
202303 -1.125 127.348 -1.176
202306 -1.331 128.729 -1.377
202309 -1.030 129.860 -1.056
202312 -0.995 129.419 -1.024
202403 -0.852 131.776 -0.861
202406 -0.325 132.554 -0.326
202409 -0.432 133.029 -0.432
202412 -0.642 133.157 -0.642

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Enlivex Therapeutics  (XTAE:ENLV) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Enlivex Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Ness Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics Headlines

From GuruFocus

Enlivex Adopts Bitcoin Treasury Reserve Strategy

By Marketwired 11-20-2024